Kristian Bowles

Search results

• 2018

  Potential for Bruton's tyrosine kinase inhibitors as additional antiplatelet agents in acute coronary syndromes

  Bhatti, M., Michail, O., Ayton, S., Gollop, N. D., Ryding, A., Rushworth, S., Bowles, K. & Flather, M., Aug 2018, In: European Heart Journal. 39, Supplement 1, p. 747-747 1 p.

  Research output: Contribution to journal › Abstract › peer-review

  Open Access

• The effect of BTK inhibitors on platelet aggregation in acute coronary syndromes

  Bhatti, M., Ayton, S., Michail, O., Gollop, N. D., Ryding, A., Rushworth, S., Bowles, K. & Flather, M., Jun 2018, In: Heart. 104, p. A7-A8 2 p.

  Research output: Contribution to journal › Abstract › peer-review
• 2011

  Elevated NRF2 levels in acute myeloid leukaemia reduces sensitivity towards proteasome inhibitors

  Rushworth, S. A., Bowles, K. M. & MacEwan, D. J., Oct 2011, In: Basic & Clinical Pharmacology & Toxicology. 109, p. 31 1 p.

  Research output: Contribution to journal › Abstract › peer-review

• Heme oxygenase-1 protects acute myeloid leukaemia cells from front line chemotherapeutic drugs

  Heasman, S-A., Zaitseva, L., Bowles, K., Rushworth, S. A. & MacEwan, D. J., Oct 2011, In: Basic & Clinical Pharmacology & Toxicology. 109, p. 96 1 p.

  Research output: Contribution to journal › Abstract › peer-review